<DOC>
	<DOCNO>NCT00011973</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness fenretinide treat patient advanced kidney cancer .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient advance renal cell carcinoma treat fenretinide . - Determine progression-free overall survival patient population treat drug . - Determine quantitative qualitative toxic effect drug patient . OUTLINE : Patients receive oral fenretinide twice day 7 day . Courses repeat every 21 day absence unacceptable toxicity disease progression . PROJECTED ACCRUAL : Approximately 18-35 patient accrue study within 9-21 month .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advanced unresectable , locally recurrent , metastatic renal cell carcinoma Measurable disease At least 20 mm conventional technique OR At least 10 mm spiral CT scan No nonmeasurable disease include : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion No known brain metastasis History brain metastasis resect and/or irradiated subsequent normal brain CT scan allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : More 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL AST great 2.5 time upper limit normal Renal : Creatinine great 2 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia Other : Not pregnant nursing Fertile patient must use effective contraception No prior malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ site No history allergic reaction attribute compound similar chemical biologic composition fenretinide No concurrent uncontrolled illness ( e.g. , ongoing active infection ) No concurrent psychiatric illness social situation would preclude study History HIV allow active infection history retinitis No history retinal disease , night blindness , difficulty see dark PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biologic therapy allow Chemotherapy : No 1 prior chemotherapy regimen Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy Surgery : See Disease Characteristics Other : Recovered prior therapy No prior systemic retinoid therapy No concurrent antioxidant ( e.g. , ascorbic acid vitamin E ) No concurrent therapy renal cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>